Emerging Biomarkers in Non–Small Cell Lung Cancer
Melinda Oliver, BA, BSN, RN, MPAP
The University of Texas MD Anderson Cancer Center, Houston, Texas
Author’s disclosures of potential conflicts of interest are found at the end of this article.
Melinda Oliver, BA, BSN, RN, MPAP, The University of Texas MD Anderson Cancer Center—Thoracic Medical Oncology, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030. E-mail: email@example.com
J Adv Pract Oncol 2017;8:51–58 |
© 2017 Harborside Press®
Since the identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small cell lung cancers and the concomitant success of front-line EGFR inhibitors in treating cancers with these mutations, interest in identifying further significant oncogenic driver mutations or biomarkers has increased. Current mutations under consideration include BRAF, MET, RET, and HER2. This article discusses the current research into these biomarkers and the significance of biomarkers for treating NSCLC.
For access to the full length article, please sign in